William (Bill) Barry
William (Bill) Barry
Senior Reseach Scientist, Rho, Inc
在 rhoworld.com 的電子郵件地址已通過驗證
Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer
SM Tolaney, WT Barry, CT Dang, DA Yardley, B Moy, PK Marcom, ...
New England Journal of Medicine 372 (2), 134-141, 2015
Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: a systematic review and meta-analysis
R Barroso-Sousa, WT Barry, AC Garrido-Castro, FS Hodi, L Min, IE Krop, ...
JAMA oncology 4 (2), 173-182, 2018
Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study
JF Liu, WT Barry, M Birrer, JM Lee, RJ Buckanovich, GF Fleming, ...
The Lancet Oncology 15 (11), 1207-1214, 2014
Homologous recombination deficiency (HRD) score predicts response to platinum-containing neoadjuvant chemotherapy in patients with triple-negative breast cancer
ML Telli, KM Timms, J Reid, B Hennessy, GB Mills, KC Jensen, Z Szallasi, ...
Clinical cancer research 22 (15), 3764-3773, 2016
Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer
S Shu, CY Lin, HH He, RM Witwicki, DP Tabassum, JM Roberts, ...
Nature 529 (7586), 413-417, 2016
Significance analysis of functional categories in gene expression studies: a structured permutation approach
WT Barry, AB Nobel, FA Wright
Bioinformatics 21 (9), 1943-1949, 2005
A pathway-based classification of human breast cancer
ML Gatza, JE Lucas, WT Barry, JW Kim, Q Wang, MD Crawford, MB Datto, ...
Proceedings of the National Academy of Sciences 107 (15), 6994-6999, 2010
Implementing a geriatric assessment in cooperative group clinical cancer trials: CALGB 360401
A Hurria, CT Cirrincione, HB Muss, AB Kornblith, W Barry, AS Artz, ...
Journal of clinical oncology 29 (10), 1290, 2011
Molecular heterogeneity and response to neoadjuvant human epidermal growth factor receptor 2 targeting in CALGB 40601, a randomized phase III trial of paclitaxel plus …
LA Carey, DA Berry, CT Cirrincione, WT Barry, BN Pitcher, LN Harris, ...
Journal of Clinical Oncology 34 (6), 542, 2016
Growing use of contralateral prophylactic mastectomy despite no improvement in long-term survival for invasive breast cancer
SM Wong, RA Freedman, Y Sagara, F Aydogan, WT Barry, M Golshan
Annals of surgery 265 (3), 581-589, 2017
Public knowledge of and attitudes toward genetics and genetic testing
SB Haga, WT Barry, R Mills, GS Ginsburg, L Svetkey, J Sullivan, ...
Genetic testing and molecular biomarkers 17 (4), 327-335, 2013
Role of vascular density and normalization in response to neoadjuvant bevacizumab and chemotherapy in breast cancer patients
SM Tolaney, Y Boucher, DG Duda, JD Martin, G Seano, M Ancukiewicz, ...
Proceedings of the National Academy of Sciences 112 (46), 14325-14330, 2015
Randomized phase III trial of paclitaxel once per week compared with nanoparticle albumin-bound nab-paclitaxel once per week or ixabepilone with bevacizumab as first-line …
HS Rugo, WT Barry, A Moreno-Aspitia, AP Lyss, C Cirrincione, E Leung, ...
Journal of Clinical Oncology 33 (21), 2361, 2015
Group A Streptococcus transcriptome dynamics during growth in human blood reveals bacterial adaptive and survival strategies
MR Graham, K Virtaneva, SF Porcella, WT Barry, BB Gowen, CR Johnson, ...
The American journal of pathology 166 (2), 455-465, 2005
CSPG4 protein as a new target for the antibody-based immunotherapy of triple-negative breast cancer
X Wang, T Osada, Y Wang, L Yu, K Sakakura, A Katayama, JB McCarthy, ...
Journal of the National Cancer Institute 102 (19), 1496-1512, 2010
Seven-year follow-up analysis of adjuvant paclitaxel and trastuzumab trial for node-negative, human epidermal growth factor receptor 2–positive breast cancer
SM Tolaney, H Guo, S Pernas, WT Barry, DA Dillon, L Ritterhouse, ...
Journal of Clinical Oncology 37 (22), 1868, 2019
Survival benefit of breast surgery for low-grade ductal carcinoma in situ: a population-based cohort study
Y Sagara, MA Mallory, S Wong, F Aydogan, S DeSantis, WT Barry, ...
JAMA surgery 150 (8), 739-745, 2015
Phase I dose escalation study of the PI3kinase pathway inhibitor BKM120 and the oral poly (ADP ribose) polymerase (PARP) inhibitor olaparib for the treatment of high-grade …
UA Matulonis, GM Wulf, WT Barry, M Birrer, SN Westin, S Farooq, ...
Annals of Oncology 28 (3), 512-518, 2017
Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer
CR Acharya, DS Hsu, CK Anders, A Anguiano, KH Salter, KS Walters, ...
Jama 299 (13), 1574-1587 [Retraction: 2012;307(5):453], 2008
Genomic strategy for targeting therapy in castration-resistant prostate cancer
P Mendiratta, E Mostaghel, J Guinney, AK Tewari, A Porrello, WT Barry, ...
Journal of clinical oncology 27 (12), 2022-2029, 2009
文章 1–20